Rehn M, Chia V, Younan D, Hooda N, Fryzek J, Suh M, Mezzi K, Soeda J. 2024. An updated systematic literature review of safety and efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus Bevacizumab in adult patients with RAS wild-type left-sided metastatic colorectal cancer. PROSPERO 2024:CRD42022338784. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42022338784.
Abstract
Review objectives: In the published peer-reviewed literature, what is the reported overall survival (OS) among RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) patients and among BRAF WT mCRC patients given epidermal growth factor receptor inhibitors (EGFRIs) + chemotherapy or bevacizumab + chemotherapy as first-line treatments? In the published peer-reviewed literature, what are the reported progression-free survival (PFS), objective response rate (ORR), resection rate (RR), and adverse events (AEs) associated with EGFRIs + chemotherapy or bevacizumab + chemotherapy given as first-line treatments in RAS WT left-sided mCRC patients and in BRAF WT mCRC patients? In the published peer-reviewed literature, what is the reported OS among RAS WT left-sided mCRC patients and among BRAF WT mCRC patients given EGFRIs + chemotherapy or bevacizumab + chemotherapy as first-line treatments by tumor sidedness (left-sided vs all-side tumor)? In the published peer-reviewed literature, what are the reported PFS, ORR, RR, and AEs associated with EGFRIs + chemotherapy or bevacizumab + chemotherapy given as first-line treatments in RAS WT left-sided mCRC patients and in BRAF WT mcRC patients by tumor sidedness (left-sided vs all-side tumor)?